Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$228.52M

FY 2025 · Annual

Net Income

-$223.12M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000011.03M
Gross Profit0000(11.03M)
Gross Margin—————
Research & Development125.48M165.57M186.34M171.24M142.02M
Selling, General & Admin41.77M58.77M73.32M101.96M86.5M
Operating Expenses167.25M224.34M259.66M273.21M217.49M
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
EBITDA(157.81M)(213.69M)(236.62M)(247.49M)(210.21M)
EBITDA Margin—————
Operating Income(167.25M)(224.34M)(259.66M)(273.21M)(228.52M)
Operating Margin—————
Interest Income3.07M3.89M15.94M18.22M10.62M
Interest Expense5.89M1.91M1.88M1.89M1.89M
Other Income / Expenses(1.82M)2.48M14.06M14.46M5.39M
Income Before Tax(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Net Margin—————
EPS (Basic)(2.68)(3.26)(2.92)(2.73)(2.01)
EPS (Diluted)(2.68)(3.26)(2.92)(2.73)(2.01)
Weighted Avg Shares63.24M68.15M84.01M94.81M111.12M
Weighted Avg Shares (Diluted)63.24M68.15M84.01M94.81M111.12M

RCKT Earnings Waterfall · TTM

NASDAQ:RCKT · Revenue to Net Income

Key Ratios

EPS$-1.87
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-1.8
P/S Ratio0.0

Analysis

$0 of revenue converted into -$209.4M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.87, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 12, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
SC 13G/ASC 13G/A filingOct 30, 2026

How much revenue does RCKT generate?

Rocket Pharmaceuticals, Inc. (RCKT) reported $0.00 of revenue in fiscal 2025.

Is RCKT profitable?

Rocket Pharmaceuticals, Inc. (RCKT) reported -$223.12M of net income.